p.s. One has to wonder if XOM will try to fold in IMO at some point instead of maintaining the awkward “arms-length” status XOM has with IMO when it comes to XOM’s dealmaking in Canada. The relationship reminds me of Roche and Genentech before Roche finally bought out the minority shareholders.
Market Data 
Markets 
AI
